Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit .
馬薩諸塞州波士頓-(新聞文件公司-2022年11月15日)-Block&Leviton正在調查Accelerate Diagnostics，Inc.(納斯達克代碼：AXDX)是否可能違反證券法。在Accelerate Diagnostics，Inc.的投資中蒙受損失的投資者應該與該公司聯繫，以瞭解他們可能如何挽回這些損失的更多信息。有關更多詳細信息，請訪問。
What is this all about?
這是怎麼回事？
After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S. Food and Drug Administration for the company to immediately discontinue marketing and distribution of its Accelerate Arc system and related BC Kit for a particular diagnostic use.
在2022年10月21日股市收盤後，Accelerate Diagnostics，Inc.披露，該公司收到美國食品和藥物管理局的請求，要求該公司立即停止營銷和分銷其Accelerate Arc系統和用於特定診斷用途的相關BC套件。
Previously, Accelerate Diagnostics had been marketing the Accelerate Arc products as Class I devices, exempting them from 510(k) clearance requirements. Recently, the FDA informed the company that marketing the products in the U.S. requires 510(k) clearance.
此前，Accelerate Diagnostics一直將Accelerate Arc產品作為I類設備進行營銷，免除了510(K)許可要求。最近，FDA通知該公司，在美國銷售該產品需要獲得510(K)許可。
Shares of Accelerate Diagnostics, Inc. stock dropped approximately 9% in premarket trading and were down more than 40% in intraday trading on October 24, 2022.
Accelerate Diagnostics，Inc.的股價在盤前交易中下跌約9%，在2022年10月24日的盤中下跌超過40%。
Who is eligible?
誰有資格？
Anyone who purchased Accelerate Diagnostics, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
任何購買了Accelerate Diagnostics，Inc.股票並虧損的人都有資格獲得資格，無論他們是否已經出售了自己的投資。投資者應聯繫Block&Leviton瞭解更多信息。
What is Block & Leviton doing?
Block&Leviton在做什麼？
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
Block&Leviton正在調查該公司是否違反了證券法，並可能提起訴訟，試圖代表損失慘重的投資者追回損失。
What should you do next?
你下一步應該做什麼？
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
如果您的投資出現虧損，您應該通過我們的Case網站、通過電子郵件Case@lockleviton.com或通過電話(617)398-5600與Block&Leviton聯繫，瞭解更多信息。
Why should you contact Block & Leviton?
你為什麼要聯繫Block&Leviton？
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, , or call (617) 398-5600 or email cases@blockleviton.com with any questions.
許多律師事務所都發布了關於這一問題的新聞稿；這些律師事務所中的大多數實際上並沒有提起證券集體訴訟。Block&Leviton律師事務所實際上是一家訴訟案件的律師事務所。我們致力於通過在全國各地的聯邦法院積極提起訴訟，代表被欺詐的投資者獲得重大賠償。美國許多頂級機構投資者聘請我們來代表他們的利益。您可以在我們的網站上了解更多關於我們的信息，或致電(617)398-5600或發送電子郵件至case@lockleviton.com，有任何疑問。
This notice may constitute attorney advertising.
本通知可構成代理廣告。
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
聯繫方式：
Block&LEVITON LLP
富蘭克林大街260號，套房1860
馬薩諸塞州波士頓，郵編：02110
電話：(617)398-5600
電子郵件：case@lockleviton.com
SOURCE: Block & Leviton LLP
消息來源：Block&Leviton LLP
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。